Secukinumab efficacy in reducing the severity and the psychosocial impact of moderate‐to‐severe psoriasis as assessed by the Simplified Psoriasis Index: results from the IPSI‐PSO study

Abstract

Background The utility of the Simplified Psoriasis Index (SPI), a recently developed multidomain tool for assessing psoriasis, was investigated in a study assessing response to secukinumab. Methods In an open‐label, multicentre study involving 17 French centres, patients with moderate‐to‐severe plaque psoriasis received secukinumab 300 mg subcutaneously once weekly from baseline to W4, then every 4 weeks until W48. Dermatologist‐scored SPI psoriasis severity (proSPI‐s) was compared with Psoriasis Area and Severity Index (PASI). Patient self‐assessed severity (saSPI‐s) and psychosocial impact (SPI‐p) were compared with PASI and Dermatology Life Quality Index (DLQI), respectively. Results We included 120 patients (69.2% male; mean age 45.9 years; mean duration of psoriasis 21.6 years). Mean baseline scores were as follows: proSPI‐s 24.9, saSPI‐s 23.5, PASI 23.1, SPI‐p 8.2 and DLQI 13.6. Severity scores achieved by 16 weeks (proSPI‐s 2.3, saSPI‐s 2.2 and PASI 2.2) were maintained to W52. Reductions in mean psychosocial impact scores were maintained to W52 (SPI‐p and DLQI, respectively, 2.1 and 1.5 at W16; 1.5 and 1.9 at W52). Conclusions Decrease of PASI scores in response to secukinumab was closely correlated with proSPI‐s, supporting the latter's suitability for assessing response to therapy. Although the correlation between PASI and saSPI‐s was slightly weaker, patients were able to complete a valid assessment of their psoriasis independently, and thus potentially remotely. With the added benefit of psychosocial impact assessment (SPI‐p), SPI provides a valid tool enabling patients to assess their own psoriasis, remotely if necessary.

PASI vs PO‐PASI: Patient‐Oriented PASI (PO‐PASI) is comparable to clinician score PASI

“…Our Pearson's r = 0.866 actively demonstrates a strong positive linear correlation between the PASI and PO-PASI scores when assessing chronic plaque psoriasis (Table 2). Our findings are in keeping with the literature [4][5][6] . However, this provides little clinical information on how much X equals Y or the equivalence of PASI and PO-PASI.…”

“…We demonstrated that PO-PASI has a good-to-excellent interrater reliability/ agreement with the 95% confidence interval ranging from 0.803 to 0.907 (Table 2). The strong agreement implies that patients and physicians have a similar perception of psoriasis severity, in keeping with published data around patient-oriented tools 6 . Furthermore, it appears that there is a stronger correlation between the PO-PASI and the PASI Link to PO-PASI tool : https://dermnetnz.org/cme/psoriasis-po- at scores lower than 15, which is the cut-off for biological treatment in Australia.…”

“…The Self-Administered PASI (SAPASI) devised more than 20 years ago was reported to have a moderate-tostrong correlation with PASI, but it is not commonly used. [4][5] The patient-oriented tool saSPI-s has also been validated against the PASI 6 .…”

Association of Secukinumab Treatment With Tuberculosis Reactivation in Patients With Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis

“…Table 1 lists details of the clinical trials selected for this analysis . Eligible patients 18 years or older with moderate-to-severe plaque psoriasis or active psoriatic arthritis or ankylosing spondylitis were enrolled in the trials according to prespecified inclusion criteria.…”

Psoriasis between Autoimmunity and Oxidative Stress: Changes Induced by Different Therapeutic Approaches

“…Novel biological drugs, which target TNF- α , the p40 subunit of IL-12 and IL-23, or IL-17 receptors, are effective in treating psoriasis and reducing the PASI score [ 78 ] ( Table 1 ). Interestingly, inhibition of IL-1, IL-6, or IFN- γ failed to achieve a significant clinical effect in psoriasis [ 79 ]. TNF- α inhibitors include etanercept, infliximab, adalimumab, certolizumab pegol, and golimumab [ 80 ].…”